in vitro News and Research

RSS

SDIX announces multi-year collaboration with Banyan Biomarkers

SDIX, today announced a multi-year collaboration with Banyan Biomarkers, Inc. to provide products and services for Banyan's biomarker discovery work in the detection of traumatic brain injury.

20 Jul 2010

StemCell Holding leads CHF 20 million investment in Pantec Biosolutions

Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced the closing of a CHF 20 million investment achieved by two financing rounds. The StemCell Holding AG, an Austrian investment company in the life sciences sector, acted as lead investor.

20 Jul 2010

Researchers reveal findings on restricted lineage of iPS cells

Adult cells that have been reprogrammed into induced pluripotent stem cells (iPS cells) do not completely let go of their past, perhaps limiting their ability to function as a less controversial alternative to embryonic stem cells for basic research and cell replacement therapies, according to researchers at Children's Hospital Boston, John Hopkins University and their colleagues

20 Jul 2010

Univfy, Stanford scientists develop first validated prognostic test for predicting IVF live birth outcomes

Univfy, a pioneer in the development of personalized in vitro fertilization (IVF) prognostic tools, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences (PNAS) by its founding scientific team and clinical collaborators from Stanford University.

20 Jul 2010

Corgenix, ELITech establish broad strategic alliance

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and the ELITech Group, a Paris, France-based, privately held group of companies and worldwide manufacturer and distributor of in-vitro diagnostic equipment and reagents, today announced a broad strategic alliance.

19 Jul 2010

FDA can promote personalized medicine by identying gaps in laboratory operations: ACLA

The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.

17 Jul 2010

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2010.

16 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

Evotec to acquire DeveloGen

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to €14m in shares plus performance-related deferred payments (earn-out).

15 Jul 2010

CardioGenics Holdings' subsidiary signs second product agreement with Merck Chimie

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company's subsidiary, CardioGenics Inc., has entered into an agreement with Merck Chimie S.A.S. to adopt its proprietary biological-linking technology to Merck-supplied magnetic beads designed to increase yields in antibody manufacturing.

15 Jul 2010

Presidio Pharmaceuticals completes Phase 1a clinical trial of PPI-461 in healthy subjects

Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a clinical trial of PPI-461, its lead HCV NS5A inhibitor, in healthy subjects. This first-in-human trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest tested dose.

14 Jul 2010

Universal surveillance for MRSA decreased HAIs related to devices: Study

Pitt County Memorial Hospital today announced results of a study demonstrating that universal surveillance for methicillin-resistant Staphylococcus aureus decreased health care-associated infections related to devices. Infection rates decreased 68 percent for ventilator-associated pneumonias; 51 percent for central line-associated bacteremias; and 49 percent for catheter-associated urinary tract infections.

14 Jul 2010

Researchers investigate oral cancer, periodontal disease relationship

Today during the 88th General Session & Exhibition of the International Association for Dental Research, in Barcelona, Spain, presenting author J. Meyle, Justus Liebig University, Giessen, Germany, will present an abstract titled "P. gingivalis Infection and Immune Evasion of Oral Carcinomas."

14 Jul 2010

SeqWright congratulates EraGen on successful FDA 510(k) market clearance of MultiCode-RTx HSV 1 & 2 Kit

EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.

13 Jul 2010

BioImage Study published in American Heart Journal

BG Medicine, Inc., a U.S.-based biomarker discovery and in vitro diagnostics company, announced today the publication of The BioImage Study trial design and key objectives in the American Heart Journal. The American Heart Journal is a peer- reviewed journal that publishes original research and review articles on clinical research studies in the field of cardiology.

13 Jul 2010

Palex to distribute MDI's Detect-Ready MRSA assay in Spain

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Palex Medical S.A., one of Spain's leading distributors of medical device and diagnostic products to hospitals, today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready™ MRSA assay in Spain.

13 Jul 2010

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.

13 Jul 2010

Amorfix Life Sciences uses A(4) test to detect accumulation of Abeta in mouse models of AD

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases including Alzheimer's disease, has used its A(4) test to compare the rate of accumulation of aggregated Abeta in the brain tissue of various mouse models of AD. Amorfix presented this new data at the International Conference on Alzheimer's Disease this week.

13 Jul 2010

Biodel reports preclinical test results of BIOD620 glucose-regulated or "smart" basal insulin product candidate

Biodel Inc. today reported results of preclinical tests which demonstrated the potential of the company's glucose-regulated or "smart" basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions. In an oral presentation today at the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, Nandini Kashyap, director of novel drug delivery at Biodel, described results of in vitro and in vivo studies with diabetic pigs which compared the use of BIOD620 to Lantus® (insulin glargine).

13 Jul 2010

Asuragen, Life Technologies announce European launch of BCR/ABL1 Quant Test

Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.

13 Jul 2010